A 62-year-old man with hypertension and BPH is started on an alpha blocker. He develops severe orthostatic hypotension and syncope on the first dose. Which alpha blocker would be the safest alternative that minimizes first-dose syncope while still treating both conditions?

Explanation

## Managing First-Dose Syncope with Alpha Blockers **Key Point:** Alfuzosin is a uroselective α1A-blocker with a lower incidence of first-dose syncope compared to non-selective agents, making it the safest alternative when first-dose hypotension occurs. ### Uroselective vs. Non-Selective Alpha Blockers | Drug | Selectivity | First-Dose Syncope Risk | Hypertension Effect | BPH Efficacy | |------|-------------|------------------------|---------------------|---------------| | **Alfuzosin** | α1A-selective | Low | Minimal | Excellent | | **Tamsulosin** | α1A-selective | Very low | Minimal | Excellent | | **Terazosin** | Non-selective | High | Significant | Good | | **Doxazosin** | Non-selective | High | Significant | Good | | **Phenoxybenzamine** | Non-selective, irreversible | Very high | Severe | Not used | **High-Yield:** Uroselective blockers (alfuzosin, tamsulosin) cause first-dose syncope in <1% of patients, while non-selective agents (terazosin, doxazosin) cause syncope in 5–15% of patients due to α1B-mediated vascular smooth muscle relaxation. ### Why Alfuzosin Is the Answer 1. **Uroselective mechanism:** Alfuzosin preferentially blocks α1A receptors in the prostate, sparing vascular α1B receptors. 2. **Lower cardiovascular risk:** Minimal first-dose hypotension and syncope compared to non-selective agents. 3. **Dual benefit:** Treats both hypertension (modest) and BPH symptoms effectively. 4. **Dosing advantage:** Alfuzosin is given as extended-release formulation (2.5 mg OD), which further reduces first-dose effects. **Clinical Pearl:** If a patient develops first-dose syncope on a non-selective blocker, switching to a uroselective agent (alfuzosin or tamsulosin) is preferred over stopping therapy. Alternatively, starting with a lower dose and titrating slowly reduces syncope risk. **Warning:** Do NOT restart the same non-selective agent at a higher dose — this will likely reproduce syncope. Switching to a uroselective agent is the correct strategy.